{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:58:55Z","timestamp":1793332735294,"version":"4.5.0"},"reference-count":28,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The PTH receptor type 1 (PTHR1) mediates the actions of two endogenous polypeptide ligands, PTH and PTHrP, and thereby plays key roles in bone biology. Based on its capacity to stimulate bone formation, the peptide fragment PTH (1\u201334) is currently in use as therapy for osteoporosis. Abaloparatide (ABL) is a novel synthetic analog of human PTHrP (1\u201334) that holds promise as a new osteoporosis therapy, as studies in animals suggest that it can stimulate bone formation with less of the accompanying bone resorption and hypercalcemic effects that can occur with PTH (1\u201334). Recent studies in vitro suggest that certain PTH or PTHrP ligand analogs can distinguish between two high-affinity PTHR1 conformations, R0 and RG, and that efficient binding to R0 results in prolonged signaling responses in cells and prolonged calcemic responses in animals, whereas selective binding to RG results in more transient responses. As intermittent PTH ligand action is known to favor the bone-formation response, whereas continuous ligand action favors the net bone-resorption\/calcemic response, we hypothesized that ABL binds more selectively to the RG vs the R0 PTHR1 conformation than does PTH (1\u201334), and thus induces more transient signaling responses in cells. We show that ABL indeed binds with greater selectivity to the RG conformation than does PTH (1\u201334), and as a result of this RG bias, ABL mediates more transient cAMP responses in PTHR1-expressing cells. The findings provide a plausible mechanism (ie, transient signaling via RG-selective binding) that can help account for the favorable anabolic effects that ABL has on bone.<\/jats:p>","DOI":"10.1210\/en.2015-1726","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T13:01:18Z","timestamp":1447333278000},"page":"141-149","source":"Crossref","is-referenced-by-count":292,"title":["Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling"],"prefix":"10.1210","volume":"157","author":[{"given":"Gary","family":"Hattersley","sequence":"first","affiliation":[{"name":"Radius Health Inc (G.H., H.B.), Waltham, Massachusetts 02451"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dean","sequence":"first","affiliation":[{"name":"Endocrine Unit (T.D., B.A.C., T.J.G.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braden A.","family":"Corbin","sequence":"first","affiliation":[{"name":"Endocrine Unit (T.D., B.A.C., T.J.G.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Bahar","sequence":"first","affiliation":[{"name":"Radius Health Inc (G.H., H.B.), Waltham, Massachusetts 02451"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Gardella","sequence":"first","affiliation":[{"name":"Endocrine Unit (T.D., B.A.C., T.J.G.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"issue":"2","key":"2020071611542208500_B1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1210\/jc.2011-2332","article-title":"Update on bone anabolics in osteoporosis treatment: Rationale, current status, and perspectives","volume":"97","author":"Baron","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071611542208500_B2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611542208500_B3","first-page":"M460","article-title":"BIM-44058, a novel analog of PTHrP with enhanced bone building activity, but decreased calcium-mobilization potential","volume":"16","author":"Culler","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2020071611542208500_B4","first-page":"SA0409","article-title":"Long term effect of BA058, a novel human PTHrP analog, restores bone mass in the aged osteopenic ovariectomized cynomolgus monkey","volume":"28","author":"Doyle","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2020071611542208500_B5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.1547","article-title":"Osteocyte RANKL: New insights into the control of bone remodeling","volume":"27","author":"Xiong","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2020071611542208500_B6","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"issue":"3","key":"2020071611542208500_B7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0022-3565(24)38276-X","article-title":"Measurement of agonist and antagonist ligand-binding parameters at the human parathyroid hormone type 1 receptor: Evaluation of receptor states and modulation by guanine nucleotide","volume":"289","author":"Hoare","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"2020071611542208500_B8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.peptides.2003.09.002","article-title":"Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: Detection, and pharmacological evaluation by peptide ligands","volume":"24","author":"Hoare","year":"2003","journal-title":"Peptides"},{"key":"2020071611542208500_B9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1210\/me.2005-0349","article-title":"Mechanisms of ligand binding to the parathyroid hormone (PTH)\/PTH-related protein receptor: Selectivity of a modified PTH(1\u201315) radioligand for GalphaS-coupled receptor conformations","volume":"20","author":"Dean","year":"2006","journal-title":"Mol Endocrinol"},{"issue":"1","key":"2020071611542208500_B10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1210\/me.2007-0274","article-title":"Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH\/PTHrP receptor","volume":"22","author":"Dean","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"15","key":"2020071611542208500_B11","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1073\/pnas.1301674110","article-title":"Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH","volume":"110","author":"Maeda","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020071611542208500_B12","first-page":"S1","article-title":"Identification and optimization of residues in PTH and PTHrP that determine altered modes of binding to the PTH\/PTHrP receptor","volume":"23","author":"Okazaki","year":"2008","journal-title":"J Bone Min Res"},{"issue":"11","key":"2020071611542208500_B13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1021\/cb200248h","article-title":"A luminescent biosensor with increased dynamic range for intracellular cAMP","volume":"6","author":"Binkowski","year":"2011","journal-title":"ACS Chem Biol"},{"issue":"41","key":"2020071611542208500_B14","doi-asserted-by":"crossref","first-page":"28382","DOI":"10.1074\/jbc.M109.022905","article-title":"Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides","volume":"284","author":"Pioszak","year":"2009","journal-title":"J Biol Chem"},{"issue":"50","key":"2020071611542208500_B15","doi-asserted-by":"crossref","first-page":"38181","DOI":"10.1074\/jbc.M606762200","article-title":"Proline-rich motifs in the parathyroid hormone (PTH)\/PTH-related protein receptor C terminus mediate scaffolding of c-Src with beta-arrestin2 for ERK1\/2 activation","volume":"281","author":"Rey","year":"2006","journal-title":"J Biol Chem"},{"issue":"8","key":"2020071611542208500_B16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2012.05.004","article-title":"Non-canonical signaling of the PTH receptor","volume":"33","author":"Vilardaga","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"2020071611542208500_B17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nchembio.545","article-title":"Retromer terminates the generation of cAMP by internalized PTH receptors","volume":"7","author":"Feinstein","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"10","key":"2020071611542208500_B18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nchembio.206","article-title":"Sustained cyclic AMP production by parathyroid hormone receptor endocytosis","volume":"5","author":"Ferrandon","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"9","key":"2020071611542208500_B19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nchembio.1589","article-title":"Endosomal GPCR signaling turned off by negative feedback actions of PKA and v-ATPase","volume":"10","author":"Gidon","year":"2014","journal-title":"Nat Chem Biol"},{"key":"2020071611542208500_B20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ceb.2013.10.008","article-title":"Recent developments in biased agonism","volume":"27","author":"Wisler","year":"2014","journal-title":"Curr Opin Cell Biol"},{"key":"2020071611542208500_B21","first-page":"me20131314","article-title":"Minireview: More than just a hammer: Ligand 'bias' and pharmaceutical discovery","author":"Luttrell","year":"2014","journal-title":"Mol Endocrinol"},{"key":"2020071611542208500_B22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.pharmtox.010909.105800","article-title":"Molecular mechanism of \u03b2-arrestin-biased agonism at seven-transmembrane receptors","volume":"52","author":"Reiter","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2020071611542208500_B23","doi-asserted-by":"crossref","first-page":"1ra1","DOI":"10.1126\/scitranslmed.3000071","article-title":"A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation","volume":"1","author":"Gesty-Palmer","year":"2009","journal-title":"Sci Transl Med"},{"issue":"16","key":"2020071611542208500_B24","doi-asserted-by":"crossref","first-page":"10856","DOI":"10.1074\/jbc.M513380200","article-title":"Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1\/2 activation","volume":"281","author":"Gesty-Palmer","year":"2006","journal-title":"J Biol Chem"},{"issue":"3","key":"2020071611542208500_B25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.112.199752","article-title":"Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways","volume":"345","author":"Cupp","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2020071611542208500_B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-010-0465-9","article-title":"Molecular basis of parathyroid hormone receptor signaling and trafficking: A family B GPCR paradigm","volume":"68","author":"Vilardaga","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"2020071611542208500_B27","first-page":"668","article-title":"Highly potent analogs of human parathyroid hormone and human parathyroid hormone-related protein","author":"Dong"},{"key":"2020071611542208500_B28","article-title":"Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?","author":"Hothersall","journal-title":"Drug Discov Today"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/157\/1\/141\/11029147\/endo0141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/157\/1\/141\/11029147\/endo0141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T07:28:18Z","timestamp":1748676498000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/157\/1\/141\/2251837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2015-1726","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725931925.793531416","asserted-by":"object"}]},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,1]]}}}